Navigation Links
Special Event Providing Exclusive Access to Shanghai's Booming Zhangjiang Pharma Valley Added to Agenda of First Annual SBS China Conference
Date:9/20/2010

CHICAGO, Sept. 20 /PRNewswire-USNewswire/ -- The Society for Biomolecular Sciences (SBS), now officially the Biomolecular Sciences Section (BSS) of the Society for Laboratory Automation and Screening (SLAS), is pleased to announce Drug Discovery in Shanghai Zhangjiang Pharma Valley, a special program and tour just added to the agenda of the First Annual SBS China Conference and Exhibition, December 7-9, 2010, at the Pudong Shangri-La Hotel in Shanghai, China.

During the afternoon of December 7, participants of Drug Discovery in Shanghai Zhangjiang Pharma Valley will engage with Chinese scientists at Zhangjiang Hi-Tech Park, a thriving center for innovation and framework for the biomedicine industry in Shanghai. The program, an exclusive opportunity available only to conference participants, will feature three 20-minute presentations offering unique perspectives on Shanghai's drug discovery initiatives. Speakers include:

  • Zhong Zhong, Ph.D., Sr. Director of Discovery Technology, GlaxoSmithKline R&D China
  • Xin Xie, Ph.D., Professor, Head, Assay Development Dept.II, The National Center of Drug Screening
  • Danyi Wen, M.D., MBA, Executive Director, Cell Biology/Pharmacology Shanghai ChemPartner, Co. Inc.

  • In addition, this unique opportunity will be highlighted by a narrated coach bus tour of the Zhangjiang Hi-Tech Park. The tour will take participants to the pharma valley that is the Shanghai home to many multi-national companies, CROs, technology providers, institutes and facilities. Some of those companies now taking residence in and around the technology park include Abbott, DSM, GlaxoSmithKline, Lilly, Novartis, Otsuka, Pfizer, Roche, PerkinElmer, Tecan, GE Healthcare, Chempartner, Sundia, WuXiApptech, and others.

    Early confirmation to participate is encouraged, as space is limited and reserved on a first-come, first-served basis. For more details and to register for the First Annual China Conference and to confirm participation in this new special event, visit sbsonline.org/China.

    The Society for Laboratory Automation and Screening (SLAS) is a new non-profit scientific organization uniting the Society for Biomolecular Sciences (SBS) and the Association for Laboratory Automation (ALA). The SLAS mission is to be the preeminent global organization providing forums for education and information exchange and to encourage the study of, improve the science and practice of, laboratory automation and screening. Watch for the official launch of SLAS.org, our new, comprehensive website, in October. For additional information, please visit sbs-alamerger.org.

    Headquartered in Danbury, CT, the Society for Biomolecular Sciences (SBS) serves as a section of SLAS, dedicated to drug discovery and its related disciplines. SBS was founded in 1994 to provide a forum for global education and information exchange among professionals in the chemical, pharmaceutical, biotech and agrochemical industries. SBS members represent many of the largest and most influential research institutes, universities and pharmaceutical companies in the world, including the National Cancer Institute; University of California, Berkeley; Harvard University; government agencies and organizations; and most major companies involved in drug discovery.Contact Information SLAS Media Relations Anne O'Day 630.305.0003 x.385 aoday@labautomation.org
    '/>"/>

    SOURCE Society for Laboratory Automation and Screening
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
    2. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
    3. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
    4. U.S. Preventive Medicine Acquires Specialty Disease Management
    5. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
    6. Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial
    7. Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
    8. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
    9. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
    10. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
    11. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/8/2016)... , Feb.8, 2016 Aesthetic Devices - ... Medical Devices sector report, "Aesthetic Devices - Medical Devices ... currently in pipeline stage. This report ... and primary research by GlobalData,s team of industry experts. ... removed or altered based on the availability and relevance ...
    (Date:2/8/2016)... SAN DIEGO , Feb. 8, 2016  Neurocrine ... the Company will report its fourth quarter and year-end ...  February 11, 2016.  Neurocrine will then host a live ... and provide a Company update Thursday afternoon, February 11, ... Time). http://www.neurocrine.com . --> http://www.neurocrine.com ...
    (Date:2/8/2016)... N.J. , Feb. 8, 2016   GS1 ... healthcare professionals to guide them through GS1 Standards implementation ... Drug Administration (FDA) Unique Device Identification (UDI) rule. ... GS1 US; Beth Gibson , senior director industry ... , industry development director, GS1 US --> ...
    Breaking Medicine Technology:
    (Date:2/8/2016)... ... February 08, 2016 , ... ... today that nominations will be accepted February 8, 2016 through May 8, ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
    (Date:2/8/2016)... ... February 08, 2016 , ... ... 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with ... time to make a change in public health,” states Carole Baggerly, Director of ...
    (Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now ... country. The AutismOne 2016 Conference, which is being held May 25-29 at the Loews ... elsewhere about helpful interventions and causes of chronic illness in children. , Very recent ...
    (Date:2/7/2016)... ... February 07, 2016 , ... ... has added Kybella® to his medical and surgical expertise. Technically known as deoxycholic ... injectable medication used as a non-surgical alternative for reduction of fat below the ...
    (Date:2/6/2016)... Pekin, IL (PRWEB) , ... February 06, 2016 ... ... the recovery phases of eating disorder treatment helps to reduce the frequency and ... “Tasks of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the ...
    Breaking Medicine News(10 mins):